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Background: Hericium erinaceus, as a commonly used medicine or food, has attracted much attention due to its
health effects when used as a home remedy for some diseases. The aim of this work was to investigate the
hypoglycemic and hypolipidemic effects of aqueous extract of Hericium erinaceus (AEHE) in streptozotocin
(STZ)-induced diabetic rats.
Methods: Diabetes was induced in Wistar rats by the administration of STZ (55 mg/kg BW.) intraperitoneally.
AEHE (100 and 200 mg/kg BW.) was administered for a period of 28 days. The effects of AEHE on glucose,
insulin, and lipid files in blood, and oxidative stress parameters in the liver were evaluated. The body weights
of rats were recorded at day 0, 14 and 28th days.
Results: The administration of AEHE for 28 days in STZ diabetic rats resulted in a significant decrease in serum
glucose level and a significant rise in serum insulin level. AEHE treatment attenuated lipid disorders. In addition, AEHE
administration increased the activities of CAT, SOD, and GSH-Px, and GSH level, and reduced MDA level in the liver
tissue significantly.
Conclusion: Our results suggest that AEHE possesses hypoglycemic, hypolipidemic, and antioxidant properties in
STZ-induced diabetes rats.
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The worldwide prevalence of diabetes for all age groups
was estimated to be 2.8% in 2000 and it is projected to
be 4.4% in 2030 [1]. Especially in developed and develop-
ing countries, type 2 diabetes mellitus is now considered
a worldwide epidemic, and is characterized by defects in
both insulin secretion and insulin action that causes a
chronic hyperglycaemic state [2]. A long-term metabolic
disorder of carbohydrate metabolism is one of the most
important causes of complications, such as angiopathy,
neuropathy, retinopathy, deficiency in the antioxidant
defense system, and lipid profile disorders [3-5].* Correspondence: liangtechb1@yahoo.com.cn
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reproduction in any medium, provided the orThere is considerable evidence demonstrating that oxi-
dative stress caused by the production of free radical is a
recognized participant in the development and progres-
sion of diabetes and its complications [6]. Hyperglycemia
induces non-enzymatic glycosylation and activation of the
polyol pathway, resulting in overproduction of reactive
oxygen species (ROS) that lead to structural damages
of liver, kidney, and pancreas [7]. These free radicals
also destroy pancreatic β-cells that produce and secrete
insulin [8]. There are many protective enzymes against
ROS, such as superoxide dismutase (SOD), glutathione
peroxidase (GPx) and catalase (CAT). Therefore, anti-
oxidants have been considered as the treatment in diabetes.
Hericium erinaceus, as a commonly used medicine or
food, has attracted much investigation due to its health
effects when used as a home remedy for some diseases.
Its fruiting bodies and the fungal mycelia exhibit varioustd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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glutinating [10], anti-microbial [11], immunomodulatory
[12], anti-aging [13], and antioxidant activities [14].
Recently, Hericium erinaceus has been reported to sig-
nificantly decrease lipid peroxidation level and increase
antioxidant enzymes activities in experimental animals [15].
Yang BK, et al. reported that an exo-biopolymer produced
from a submerged mycelial culture of Hericium erinaceus
possesses hypolipidemic effect in dietary-induced hyperlip-
idemic rats [16], but the effects of Hericium erinaceus
on hyperglycaemia, hyperlipidemia, lipid peroxidation
and antioxidant enzymes activities in diabetes have not
yet been examined. The present investigation was aimed
to study the possible antihyperglycemic, antihyperlipidemic,
and antioxidant effect of aqueous extract from Hericium
erinaceus (AEHE) in STZ-induced diabetic rats.
Methods
Preparation of aqueous extract of Hericium erinaceus
Hericium erinaceus powder was purchased from Shanghai
Kangzhou Company, People’s Republic of China. Strepto-
zotocin and glibenclamide were purchased from Sigma
Chemical Company (Shenyang, China). All chemicals and
solvents used were of high purity and analytical grade.
Animals
The normoglycemic male Wistar rats (160-180 g) were
used as the animal model. The rats were obtained from the
Animal Center of China Medical University. The rats were
kept in polypropylene cages under controlled temperature,
humidity, and 12 h/12 h light/dark cycles, and were fed
standard LAD 1000 M Rodent purified diet (GB 14924.3-
2010, Trophic Anima Feed High-tech Co Ltd, China)
and water ad libitum. All experiments complied with the
Guidelines on Ethical Standards for the investigation in ani-
mals; the study was approved by China Medical University
Committee for the care and use of laboratory animals.
Induction of experimental diabetes
Diabetes was induced by a single intraperitoneal injection
of freshly prepared STZ [55 mg/kg body weight (b.w.)] in
0.1 M citrate buffer (pH 4.5), and subsequently allowed
to drink 5% glucose solution overnight to overcome the
drug-induced hypoglycemic mortality. Rats with a fasting
plasma glucose ≥250 mg/dl on the third day after the STZ
injection were considered diabetic and used for the study.
Animal experiment design
A total of 48 rats (32 diabetic rats, 16 normal rats) were
used in the experiment. The rats were divided into six
groups of eight each. An oral administration of the AEHE
(100 and 200 mg/kg b.w.) and glibenclamide (30 mg/kg b.w.)
were given for 28 consecutive days. The body weights of
rats were recorded at day 0, 14 and 28th days.The experimental groups (8 rats / group) were as follows:
Group I (NM group), normal control rats treated
with vehicle alone.
Group II (NM + AEHE group), normal control rats
treated with AEHE (100 mg/kg b.w.).
Group III (DM group), diabetic control rats treated
with vehicle alone.
Group IV (DM + LAEHE group), diabetic rats were
given AEHE (100 mg/kg b.w.).
Group V (DM +HAEHE group), diabetic rats were
given AEHE (200 mg/kg b.w.).
Group VI (DM +Gli group), diabetic rats were given
glibenclamide (30 mg/kg b.w.).
At the end of the experiment, the rats were anesthe-
tized and sacrificed by decapitation. The liver were
sampled and stored at −80°C till use.
Measurement of blood glucose and insulin
On day 0 (just after last treatment of STZ), 14, and 28th,
blood samples in all groups were collected, and immedi-
ately centrifuged at 3000 × g for 20 min to obtain serum
for biochemical estimations. The blood glucose was evalu-
ated by glucose oxidase - peroxidase method (Zhongsheng
Clinical Reagent Co., Ltd, Beijing, China). Serum insulin
levels were measured by ELISA method using a commer-
cial kit (Millipore, China).
Measurement of serum lipid files
At the end of the experiment, serum levels of total choles-
terol (TC), high density lipoprotein cholesterol (HDL-C),
low density lipoprotein cholesterol (LDL-C), and triglycer-
ide (TG) were determined using commercially available kits
(Zhongsheng Clinical Reagent Co., Ltd, Beijing, China).
Measurement of oxidative stress parameters in liver
Liver of rats were removed and placed in 10% KCl
(10 ml/g tissue), and homogenized on ice for 120 s with
a DY89-II homogenizer (Ningbo Scientz Biotechnology
Co. Ltd. China) at 600 rpm. Tissue homogenates were
centrifuged at 1000 × g at 4°C for 10 min to remove tis-
sue debris, and clear supernatant was used for further
analyses. The superoxide dismutase (SOD), glutathione
peroxidase (GSH-Px) and catalase (CAT) activities, gluta-
thione (GSH) and malondialdehyde (MDA) in liver sam-
ples were measured using commercially available kits
(Jiancheng Bioengineering Institute, Nanjing, China).
Statistical analysis
Statistical analyses were performed using SPSS15.0 (SPSS,
Chicago, IL). All the experimental data were expressed as
mean ± standard deviation (SD). For significance verification
by groups, one-way or two-way ANOVA was performed,
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ANOVA was used to examine the overall effects of treat-
ment and time on the change in blood glucose and insulin
levels. A P value of <0.05 was considered significant.
Results
Effect of AEHE on body weights of rats
The body weight was recorded at day 0, 14 and 28th and
the final data were shown in Table 1. The body weights
of diabetic rats were similar to that of normal controls
just after STZ injection (P > 0.05). The bodyweights of the
diabetic control rats were significantly lower compared to
normal control group at day 14 and 28th (P < 0.05). The
diabetic control rats gained less body weights than nor-
mal control group throughout the experiment. But, body
weight gains were significantly increased in rats adminis-
trated with AEHE and glibenclamide, respectively.
Effect of AEHE on levels of blood glucose and insulin
Table 2 depicts the serum glucose levels in normal and
diabetic rats supplemented with AEHE and glibenclamide.
STZ-treated diabetic rats showed significant increase in
the levels of blood glucose when compared to normal rats
(P < 0.05). Serum glucose level was measured in normal
and diabetes rats on day 0, 14, and 28th of drug treatment.
After treatment with AEHE at 100 and 200 mg/kg b.w.
the blood glucose levels on day 14 and 28th were signifi-
cantly reduced compared to those on day 0 (P < 0.01). The
glibenclamide treated rats also showed significant reduc-
tion in serum glucose level (P < 0.05). Therefore, AEHE
and glibenclamide administration attenuated hyperglycemia
observed in the rats, while no significant changes were ob-
served in NM, NM+AEHE, and DM groups (P > 0.05).
Moreover, at the same day, serum glucose in AEHE and
glibenclamide treated rats were significantly reduced when
compared with diabetes control rats (P < 0.05).
Data concerning the fasting serum insulin levels
were presented in Table 3. After 28 day period, insulin
level decreased significantly in DM group. But, both
100 mg/kg b.w. and 200 mg/kg b.w. AEHE groups
showed higher levels of insulin at day 14 and day 28
significantly compared with the diabetic control (P < 0.05),
and the glibenclamide treated rats also showed signifi-
cant increase in insulin level (P < 0.05). In addition,Table 1 Effect of AEHE on body weights in experimental rats
Days NM NM+AEHE DM
Day 0 Body weights (g) 169.3 ± 6.2 170.6 ± 6.9 172
Day 14 Body weights (g) 211.6 ± 12.1 207.0 ± 10.0 181
Day 28 Body weights (g) 302.3 ± 8.6 297.8 ± 11.0 226
Values are expressed as mean ± SD in each group. NM group: normal control rats treat
(100 mg/kg b.w.); DM group: diabetic control rats treated with vehicle alone; DM+ LAE
diabetic rats were given AEHE (200 mg/kg b.w.); DM+Gli group: diabetic rats were giv
compared to the NM group; bindicates statistical significance of P < 0.01 compared to100 mg/kg b.w. AEHE itself did not influence insulin
level of rats in NM + AEHE group. Furthermore, no
interaction effects (treatment × time) were seen on insu-
lin levels (P > 0.05).
Effect of AEHE on levels of serum lipid files
At the end of the experiment the levels of serum TC,
TG, HDL-C and LDL-C in different experimental groups
were shown in Table 4. The results showed that serum
TG, TC and LDL-C levels were significantly increased
(P <0.05), whereas the serum HDL-C level was signifi-
cantly decreased in DM group as compared to NM
group (P < 0.05). After the administration of AEHE
(200 mg/kg b.w.) for 28 days, a significant decrease in
TG, TC, and LDL-C, and a significant increase in HDL-C
were observed in DM+HAEHE group compared with
DM group (P < 0.05). Moreover, after the administration
of AEHE (100 mg/kg b.w.) for 28 days, the alteration in
lipid metabolism was partially attenuated as evidenced by
decreased serum TG and TC levels in DM + LAEHE
group when compared with DM group (P < 0 .05).
Effect of AEHE on levels of oxidative stress parameters in
liver tissue
Figure 1(A-E) showed the activities of enzymatic antiox-
idants SOD, CAT, GSH-Px, protein antioxidant GSH,
and lipid peroxidation product MDA in the liver of ex-
perimental rats. A significant decrease of the activities
of SOD, CAT, GSH-Px, the level of GSH, and an in-
crease of MDA in the liver tissue were observed in the
DM group compared with NM group (P <0 .05). The
level of GSH and the activities of SOD, CAT, GSH-Px
were significantly restored in the AEHE treated diabetic
rats (DM + LAEHE group and DM +HAEHE group)
(P < 0.05). However, AEHE supplementation did not alter
the level of GSH and the activities of SOD, CAT, GSH-Px
significantly in NM+AEHE group (P > 0.05). In addition,
AEHE administration significantly lowered MDA level in
the diabetic rats (P <0 .05), while no effect was observed
in the normal control rats (P > 0.05).
Discussion
In diabetes mellitus, chronic hyperglycemia produces
multiple biochemical abnormalities [17,18], and studiesDM+ LAEHE DM+HAEHE DM+Gli
.4 ± 6.0 174.1 ± 6.5 169.6 ± 7.1 173.0 ± 6.8
.1 ± 9.4a 193.5 ± 13.1a,b 203.3 ± 12.6a,b 209.4 ± 12.9b
.3 ± 9.8a 251.0 ± 10.2a,b 291.3 ± 12.1b 292.2 ± 10.5b
ed with vehicle alone; NM+ AEHE group: normal control rats treated with AEHE
HE group: diabetic rats were given AEHE (100 mg/kg b.w.); DM+ HAEHE group:
en glibenclamide (30 mg/kg b.w.). aindicates statistical significance of P < 0.01
the DM group.
Table 2 Effect of AEHE on serum glucose levels in rats during the experiment days
NM NM+AEHE DM DM+ LAEHE DM+HAEHE DM+ Gli
Day 0 105.6 ± 7.8 109.3 ± 8.6 278.9 ± 11.2a 286.3 ± 9.4a 291.0 ± 11.9a 289.1 ± 10.3a
Day 14 106.1 ± 8.1 103.4 ± 7.2 289.7 ± 10.4a 226.5 ± 8.7a,b,c 199.6 ± 12.5a,b,c 202.3 ± 8.5a,b,c
Day 28 107.3 ± 7.0 98.3 ± 9.9 296.1 ± 8.8a 163.2 ± 9.6a,b,c 135.4 ± 10.9a,b,c 129.3 ± 8.3a,b,c
Values are expressed as mean ± SD in each group. NM group: normal control rats treated with vehicle alone; NM+ AEHE group: normal control rats treated with AEHE
(100 mg/kg b.w.); DM group: diabetic control rats treated with vehicle alone; DM+ LAEHE group: diabetic rats were given AEHE (100 mg/kg b.w.); DM+ HAEHE group:
diabetic rats were given AEHE (200 mg/kg b.w.); DM+Gli group: diabetic rats were given glibenclamide (30 mg/kg b.w.). aindicates statistical significance of P < 0.05
compared to the NM group; bindicates statistical significance of P < 0.05 compared to the DM group. cindicates statistical significance of P < 0.05 compared to the same
group at day 0.
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contribution of oxidative stress to the pathogenesis of
diabetes [19-21]. Clinical studies have demonstrated
that tight control of hyperglycaemia can reduce the
occurrence or progression of diabetes; however, with
the current hypoglycemic or antidiabetic drugs, it is
difficult to achieve and/or maintain tight glycemic control
in diabetic patients [22-24]. Many studies indicate that
multiple drugs are required to achieve optimal glycemic
target in many diabetic patients. Currently, one of such
complementary options is the potential of “concurrently
targeting hyperglycemia and oxidative stress” [25]. There-
fore, the use of alternate therapies that specifically target
oxidative stress implicated in diabetes may be advanta-
geous in addition to a strict glucose control.
In China, many herbs have been used to treat diabetes.
A total of more than 400 species were reported to dis-
play hypoglycemic effects [26], and Hericium erinaceus
and its components have attracted interest in the medical
research during the past two decades because of its various
biological and clinical properties, as well as its antioxidant
activity. Hericium erinaceus contains polysaccharides, oligo-
saccharide, sterol, fatty acid, erinacine, hericenone, and so
on. Wang HX, et al. found that a laccase with inhibitory
activity toward HIV-1 reverse transcriptase, was isolated
from Hericium erinaceus [27]. Nagai K, et al. reported
that dilinoleoyl-phosphatidylethanolamine extracted from
Hericium erinaceus was one of the molecules effective at
reducing ER-stress dependent cell death in the mouse
neuroblastoma cell line [28]. Kim SP, et al. demonstrated
that the extracts from Hericium erinaceus against bac-
terium infection in mice occur through the activation
of innate immune cells [12]. Han ZH, et al. reported
that Hericium erinaceus can significantly decrease lipidTable 3 Effect of AEHE on insulin levels in rats during the exp
NM NM+ AEHE DM
Day 0 20.4 ± 1.0 21.1 ± 1.3 9.6 ± 0.9a
Day 14 21.2 ± 1.2 21.6 ± 1.2 9.4 ± 1.1a
Day 28 20.9 ± 1.2 22.4 ± 1.1 9.7 ± 1.2a
Values are expressed as mean ± SD in each group. NM group: normal control rats treat
(100 mg/kg b.w.); DM group: diabetic control rats treated with vehicle alone; DM+ LAE
diabetic rats were given AEHE (200 mg/kg b.w.); DM+Gli group: diabetic rats were giv
compared to the NM group; bindicates statistical significance of P < 0.05 compared to
group at day 0.peroxidation level and increase antioxidant enzymes
activities in experimental animals [15]. Many studies
have been performed for examining its pharmacological
function in many diseases. In this study, we investigated
the antidiabetic and antioxidant effects of AEHE in STZ-
induced diabetic model rats compared with glibenclamide
treated rats, which was diabetic control group, and evalu-
ated the possible function of AEHE as a complementary
medicine on glycemic control. Glibenclamide, a standard
hypoglycemic drug, has been widely used for many years
to treat diabetes by promoting insulin secretion through
blockade of ATP-dependent potassium channels in the
pancreatic β-cells [29]. Our results in the study indicate
that the still insulin producing cells appear to be functional
in releasing insulin responsible for most of the metabolic
effects. The effect of AEHE in our study is similar to
that of glibenclamide, which suggested the mechamism
of AEHE may be also similar to that of glibenclamide.
STZ-induced diabetic rats are one of the animal models
of human insulin-dependent diabetes mellitus [30]; these
rats are characterized by high fasting blood glucose levels
and drastic reduction in blood insulin concentration [31].
In our study, serum glucose levels were measured on day
0, 14 and 28th. Till day 28th, serum glucose levels were
significantly decreased compared with those obtained on
day 0 and 14th. All results showed that the daily adminis-
tration of the AEHE during 28 days abolished the blood
glucose increase in the STZ- induced diabetic rats, and
this effect was dose dependent. Moreover, administration
of AEHE to diabetic rats resulted in a significant increase
in insulin levels. The possible mechanism by which AEHE
exhibits antihyperglycemic action in diabetic rats may be
due to the pancreatic production of insulin from the
existing β-cells or by its release from the bound form.eriment days
DM+ LAEHE DM+ HAEHE DM+Gli
9.8 ± 0.9a 10.1 ± 1.1a 9.9 ± 0.9a
12.4 ± 1.2a,b,c 16.3 ± 1.3a,b,c 15.8 ± 1.2a,b,c
16.4 ± 1.1a,b,c 18.9 ± 1.4a,b,c 18.6 ± 1.6a,b,c
ed with vehicle alone; NM+ AEHE group: normal control rats treated with AEHE
HE group: diabetic rats were given AEHE (100 mg/kg b.w.); DM+ HAEHE group:
en glibenclamide (30 mg/kg b.w.). aindicates statistical significance of P < 0.05
the DM group, cindicates statistical significance of P < 0.05 compared to the same
Table 4 Effect of AEHE on levels of serum TC, TG, HDL-C and LDL-C in experimental rats
NM NM+ AEHE DM DM+ LAEHE DM+ HAEHE DM+Gli
TG (mmol/L) 1.39 ± 0.31 1.41 ± 0.39 2.51 ± 0.36a 2.01 ± 0.41b 1.46 ± 0.37c 1.42 ± 0.31c
TC (mmol/L) 1.67 ± 0.29 1.72 ± 0.35 2.69 ± 0.32a 2.13 ± 0.41c 1.71 ± 0.31c 1.72 ± 0.34c
HDL-C (mmol/L) 1.24 ± 0.25 1.29 ± 0.29 0.89 ± 0.29a 1.01 ± 0.20 1.19 ± 0.23b 1.22 ± 0.26b
LDL-C (mmol/L) 0.54 ± 0.07 0.61 ± 0.09 0.81 ± 0.12a 0.77 ± 0.09 0.65 ± 0.06c 0.59 ± 0.08c
Values are expressed as mean ± SD in each group. NM group: normal control rats treated with vehicle alone; NM+ AEHE group: normal control rats treated with AEHE
(100 mg/kg b.w.); DM group: diabetic control rats treated with vehicle alone; DM+ LAEHE group: diabetic rats were given AEHE (100 mg/kg b.w.); DM+ HAEHE group:
diabetic rats were given AEHE (200 mg/kg b.w.); DM+Gli group: diabetic rats were given glibenclamide (30 mg/kg b.w.). aindicates statistical significance of P < 0.05
compared to the NM group; bindicates statistical significance of P < 0.05 compared to the DM group. cindicates statistical significance of P < 0.01 compared to the
DM group.
Figure 1 Effect of AEHE treatment on hepatic oxidative stress markers in experimental rats. (A) glutathione levels (GSH levels, μg/mg protein),
(B) glutathione peroxidase levels (GSH-Px levels, μg/mg protein ), (C) superoxide dismutase activity (SOD activity, U/mg protein), (D) catalase activity
(CAT activity, U/mg protein), and (E) malondialdehyde levels (MDA levels, μg/mg protein). Group I: normal control rats treated with vehicle alone;
Group II: normal control rats treated with AEHE (100 mg/kg b.w.); Group III: diabetic control rats treated with vehicle alone; Group IV: diabetic rats were
given AEHE (100 mg/kg b.w.); Group V: diabetic rats were given AEHE (200 mg/kg b.w.); Group VI: diabetic rats were given glibenclamide (30 mg/kg b.w.).
a indicates statistically different from NM group, b indicates statistically different from DM group.
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hypoglycemic or antidiabetic effect of some natural herb
extracts can be attributed to their insulin-trophic effect
that enables the reduction of blood glucose levels, liver
glycogen content, and serum lipids through the control
of serum insulin [32,33]. Similarly, our results also show
that AEHE administration increased insulin production.
Diabetic rats showed marked reduction in their body
weights compared to normal rats, which could be due
to the degradation of structural proteins. The excessive
catabolism of protein to provide amino acids for gluco-
neogenesis during insulin deficiency resulted in muscle
wasting and weight loss in diabetic untreated rats. STZ,
as a highly cytotoxic agent of pancreatic β-cells, induces
diabetes by damaging the cells that causes the reduction
in insulin release [34]. Our data indicate that rise in in-
sulin levels upon treatment with AEHE in diabetic rats
resulted in improved glycemic control, which prevented
the loss of body weight.
Abnormality in lipid metabolism in diabetes, which
are often important determinants of the course and
status of the diseases, are characterized by increase in
TC, TG, LDL-C and fall in HDL-C [34]. Moreover,
Ghoul JE, et al. have demonstrated that the deficiency
in insulin or the insulin resistance may be responsible
for hyperlipidaemia due to the insulin inhibiting action
on the key enzyme in the cholesterol biosynthesis [35].
In our study, we recorded a significant increase in the
serum levels of TG, TC and LDL-C, and a significant
decrease in the serum level of HDL-C in STZ-induced
diabetic rats; AEHE administration decreased serum TG,
TC and LDL-C levels, and increased HDL-C level in STZ-
induced diabetic rats. It indicates that AEHE treatment
is useful to normalize the lipid profile by regulating
blood glucose and insulin.
Oxidative stress in diabetes coexists with a decrease in
the antioxidant status [36], and hyperglycemia is known
to accentuate oxidative stress in liver [37]. The elevated
generation of ROS and the simultaneous decline in
antioxidative defence mechanisms observed in diabetic
patients could promote the development of neuropathy,
nephropathy, retinopathy and vascular disorders [38].
Our results demonstrated that the activities of antioxidant
enzymes (SOD, CAT and GSH-Px), and antioxidant (GSH)
in the liver of the diabetic rats were significantly lower
than those in the normal control group. However, they
were restored in AEHE treated diabetic rats, implying
that AEHE could scavenge oxygen free radicals. MDA is
a reliable marker of lipid peroxidation. Our results
showed that MDA level was significantly increased in
the liver of untreated diabetic rats, and AEHE treatment
attenuated lipid peroxidation. Moreover, increased MDA
level in the liver clearly indicates the role of oxidative
stress in diabetes, and AEHE might reduce lipid peroxidationby modulating glucose/insulin system. To sum up, AEHE
has direct or indirect antidiabetogenic effects by decreas-
ing oxidative stress, and this may be one of the reasons
that AEHE improves glycometabolism. Thus, the present
investigation showed that AEHE possess potent antioxidant
activity, which may be responsible for its hypoglycemic and
hypolipidemic properties.
Conclusion
According to our present findings, AEHE possessed a
significant anti-hyperglycemic and anti-hyperlipidemic
effect in STZ- induced diabetic rats. AEHE also can restore
the antioxidant status in treated diabetic rats. However, fur-
ther research is needed to gain a better understanding of
its potential therapeutic action, the implicated phyto-
chemical constituents and the exact mechanism of action.
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